Drug Trial Radar · NCT05737940
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Apr 24, 2023
Primary completion
Jul 15, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Feb 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
Conditions
- Pulmonary Hypertension (World Health Organization Group 2)
- Heart Failure
Interventions
AZD3427Drug
The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.
PlaceboDrug
The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Baseline to Week 25
Locations
60 sites in 14 countries. Site status is shown where the registry gives one.
Research Site
Beverly Hills, California
Research Site
La Jolla, California
Research Site
New Haven, Connecticut
Research Site
Baltimore, Maryland
Research Site
St Louis, Missouri
Research Site
Omaha, Nebraska
Research Site
Rock Hill, South Carolina
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
London, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Guangzhou, China
Research Site
Kunming, China
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Prague, Czechia
Research Site
Aarhus, Denmark
Research Site
Copenhagen, Denmark
Research Site
Berlin, Germany
Research Site
Cologne, Germany
Research Site
Frankfurt, Germany
Research Site
Jena, Germany
Research Site
Brescia, Italy
Research Site
Genoa, Italy
Research Site
Marche, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Trieste, Italy
Research Site
Bunkyō City, Japan
Research Site
Kasugai-shi, Japan
Research Site
Kure-shi, Japan
Research Site
Nagoya, Japan
Research Site
Sapporo, Japan
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.